Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Gross Margin (2020 - 2025)

Journey Medical (DERM) has disclosed Gross Margin for 5 consecutive years, with 66.2% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin fell 324.0% year-over-year to 66.2%, compared with a TTM value of 65.7% through Sep 2025, up 1393.0%, and an annual FY2024 reading of 62.81%, up 118.0% over the prior year.
  • Gross Margin was 66.2% for Q3 2025 at Journey Medical, down from 67.09% in the prior quarter.
  • Across five years, Gross Margin topped out at 152.75% in Q4 2023 and bottomed at 43.05% in Q3 2021.
  • Average Gross Margin over 5 years is 63.99%, with a median of 61.45% recorded in 2024.
  • The sharpest move saw Gross Margin skyrocketed 10122bps in 2023, then tumbled -8711bps in 2024.
  • Year by year, Gross Margin stood at 45.62% in 2021, then grew by 13bps to 51.52% in 2022, then soared by 196bps to 152.75% in 2023, then crashed by -57bps to 65.64% in 2024, then rose by 1bps to 66.2% in 2025.
  • Business Quant data shows Gross Margin for DERM at 66.2% in Q3 2025, 67.09% in Q2 2025, and 63.54% in Q1 2025.